Verapamil and diltiazem inhibit L-type calcium channels in cardiac nodal tissue. This action slows phase 0 depolarization, which prolongs conduction through the atrioventricular node. Because impulses reach the ventricles less rapidly, the ventricular response to fast atrial activity decreases, helping control rhythms driven by excessive AV nodal conduction.
A prolonged PR interval indicates slower conduction from the atria to the ventricles through the AV node. With Class IV therapy, this effect can reduce how many atrial impulses produce ventricular contractions. The result is a lower heart rate and improved control of rapid ventricular responses during certain supraventricular tachyarrhythmias.
L-type calcium-channel inhibition reduces the calcium-dependent depolarization that supports impulse conduction in cardiac nodal tissue. By slowing this electrical process, verapamil and diltiazem limit AV nodal transmission rather than simply targeting atrial activity itself. This mechanism is especially relevant when rapid atrial impulses are reaching the ventricles too frequently.
These drugs may be used when atrial fibrillation or atrial flutter produces an excessively rapid ventricular response. Their AV nodal effects reduce the number of atrial impulses conducted to the ventricles, helping lower the heart rate. They can also terminate or prevent certain supraventricular tachyarrhythmias, depending on the rhythm and clinical circumstances.
By slowing AV nodal conduction and increasing the PR interval, verapamil and diltiazem can reduce ventricular activation during rapid atrial rhythms. In certain supraventricular tachyarrhythmias, this control may terminate an episode or help prevent recurrence. Their principal therapeutic outcome is better regulation of ventricular rate rather than elimination of every atrial impulse.
Excessive suppression of cardiac nodal conduction can produce bradycardia or impaired conduction, while reduced cardiac activity may contribute to hypotension. These possible outcomes are important because the same electrophysiological effects that control rapid rhythms can become harmful when too pronounced. Consequently, pharmacological use requires careful clinical judgment regarding their effects on heart rate and conduction.